Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 63, Issue -, Pages 58-65Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2018.07.023
Keywords
Adenosine; gastric cancer; A2aR signaling; immunotherapy
Categories
Funding
- Top six talents project of Jiangsu Province [2014-wsw-032]
- Natural Science Foundation of Jiangsu Province [BK201508]
Ask authors/readers for more resources
Adenosine (ADO), generated by the ectonucleotidase CD39 and CD73 from ATP, interacts with its specific G protein-coupled receptors, which can impair anti-tumor immune responses inhibiting the infiltration and function of CD8(+) T cell and natural killer cell. Recent studies have also identified that ADO pathway plays a critical role in tumor immune surveillance, especially for some non-solid cancers. In addition, although immune checkpoint therapy targeting ADO pathway in gastric cancer is still in an early phase, encouraging results have come out from some drugs targeting ADO pathway. Therefore, target ADO signaling may be a new promising strategy to treat gastric cancer. In this review, we summarized recent works on the role of ADO in cancer immunotherapy and also discussed relative mechanisms underlying the function of ADO signaling in cancer immune responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available